Biotech PTC to acquire Lynnfield's Agilis in $200M deal

New Jersey-based drug developer PTC Therapeutics Inc. announced Thursday that it is purchasing Agilis Biotherapeutics Inc., a Lynnfield gene therapy biotech, for $200 million in cash and stock. PTC (Nasdaq: PTCT) said it would pay $50 million in cash and $150 million in PTC stock to acquire Agilis. The privately held biotech is developing gene therapies for rare and often fatal nervous system diseases, including a disorder called AADC Deficiency that inhibits motor control and the abili ty to swallow…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news